These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 17015875)

  • 61. Altitude illness: update on prevention and treatment.
    Eide RP; Asplund CA
    Curr Sports Med Rep; 2012; 11(3):124-30. PubMed ID: 22580489
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into "responders".
    Eardley I
    Eur Urol; 2006 Jul; 50(1):31-3. PubMed ID: 16517052
    [No Abstract]   [Full Text] [Related]  

  • 63. Tadalafil as treatment for idiopathic pulmonary arterial hypertension.
    de Carvalho AC; Hovnanian AL; Fernandes CJ; Lapa M; Jardim C; Souza R
    Arq Bras Cardiol; 2006 Nov; 87(5):e195-7. PubMed ID: 17396193
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Therapeutic approaches to pulmonary hypertension in hemoglobinopathies: Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathy.
    Derchi G; Forni GL
    Ann N Y Acad Sci; 2005; 1054():471-5. PubMed ID: 16339700
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Acute mountain sickness: pathophysiology, prevention, and treatment.
    Imray C; Wright A; Subudhi A; Roach R
    Prog Cardiovasc Dis; 2010; 52(6):467-84. PubMed ID: 20417340
    [TBL] [Abstract][Full Text] [Related]  

  • 66. PDE5 inhibitors: looking beyond ED.
    Jackson G
    Int J Clin Pract; 2003 Apr; 57(3):159-60. PubMed ID: 12723713
    [No Abstract]   [Full Text] [Related]  

  • 67. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
    Humbert M
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
    [No Abstract]   [Full Text] [Related]  

  • 68. Sildenafil improves walk distance in idiopathic pulmonary fibrosis.
    Collard HR; Anstrom KJ; Schwarz MI; Zisman DA
    Chest; 2007 Mar; 131(3):897-899. PubMed ID: 17356110
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Phosphodiesterase inhibitors in clinical practice. The present and the future. Part II].
    Baksheev BI; Kolomiets NM
    Klin Med (Mosk); 2007; 85(4):4-11. PubMed ID: 17564028
    [TBL] [Abstract][Full Text] [Related]  

  • 70. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Lau DH; Thompson CS; Morgan RJ; Mumtaz FH; Mikhailidis DP
    BJU Int; 2005 Dec; 96(9):1424. PubMed ID: 16287475
    [No Abstract]   [Full Text] [Related]  

  • 71. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Phosphodiesterase-5 inhibitor with broad temporal effectiveness window].
    MMW Fortschr Med; 2004 Apr; 146(16):62. PubMed ID: 15222506
    [No Abstract]   [Full Text] [Related]  

  • 73. Erectile dysfunction and cardiovascular considerations: managing patients effectively with phosphodiesterase type 5 inhibitors.
    Hutter AM
    Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I1-2. PubMed ID: 15115188
    [No Abstract]   [Full Text] [Related]  

  • 74. [High altitude pulmonary edema: the importance of early diagnosis].
    Pratali L; Cavana M; Giardini G
    Recenti Prog Med; 2010 May; 101(5):212-8. PubMed ID: 20590018
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension.
    Schwartz BG; Kloner RA
    Circulation; 2010 Jul; 122(1):88-95. PubMed ID: 20606131
    [No Abstract]   [Full Text] [Related]  

  • 76. Lung fluid movements in hypoxia.
    Sartori C; Rimoldi SF; Scherrer U
    Prog Cardiovasc Dis; 2010; 52(6):493-9. PubMed ID: 20417342
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
    Reffelmann T; Kloner RA
    Circulation; 2003 Jul; 108(2):239-44. PubMed ID: 12860892
    [No Abstract]   [Full Text] [Related]  

  • 78. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
    Hoeper MM
    Eur Respir J; 2007 Mar; 29(3):432-4. PubMed ID: 17329488
    [No Abstract]   [Full Text] [Related]  

  • 79. Carrying short-acting nitrates is not a contra-indication to the use of PDE5 inhibitors.
    Cardiovasc J S Afr; 2004; 15(1):38. PubMed ID: 15095746
    [No Abstract]   [Full Text] [Related]  

  • 80. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
    Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
    Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.